Shares of Urogen Pharma (NASDAQ:URGN) have been assigned a consensus broker rating score of 1.25 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and three have given a strong buy rating to the company.

Analysts have set a one year consensus price target of $28.00 for the company and are forecasting that the company will post ($0.05) earnings per share for the current quarter, according to Zacks. Zacks has also given Urogen Pharma an industry rank of 105 out of 265 based on the ratings given to its competitors.

URGN has been the subject of a number of recent analyst reports. Zacks Investment Research raised Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Wednesday, August 2nd. Oppenheimer Holdings, Inc. set a $32.00 price objective on Urogen Pharma and gave the company a “buy” rating in a research report on Monday, August 14th.

ILLEGAL ACTIVITY WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/04/zacks-urogen-pharma-urgn-given-consensus-rating-of-strong-buy-by-brokerages.html.

A number of large investors have recently added to or reduced their stakes in the stock. FMR LLC acquired a new position in Urogen Pharma in the 2nd quarter valued at $13,892,000. Hillhouse Capital Management Ltd. acquired a new position in Urogen Pharma in the 2nd quarter valued at $6,363,000. Jennison Associates LLC acquired a new position in Urogen Pharma in the 2nd quarter valued at $3,168,000. Wildcat Capital Management LLC acquired a new position in Urogen Pharma in the 2nd quarter valued at $2,439,000. Finally, Menora Mivtachim Holdings LTD. acquired a new position in Urogen Pharma in the 2nd quarter valued at $2,331,000. 36.06% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma (NASDAQ URGN) traded down 3.41% during midday trading on Wednesday, reaching $30.88. The company had a trading volume of 34,583 shares. The company’s 50-day moving average is $26.18 and its 200 day moving average is $20.40. The company’s market cap is $401.75 million. Urogen Pharma has a 52-week low of $13.01 and a 52-week high of $33.77.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.